Visilizumab

Item number	Size	Datasheet	Manual	SDS	Delivery time	Price
TGM-T76839-1mg	1 mg	-	-	-	7 - 10 business days*	310.00€
TGM-T76839-10mg	10 mg	-	-	-	7 - 10 business days*	1,260.00€
TGM-T76839-25mg	25 mg	-	-	-	7 - 10 business days*	1,877.00€
TGM-T76839-50mg	50 mg	-	-	-	7 - 10 business days*	2,541.00€

If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk

Description: Visilizumab is a humanized IgG2 monoclonal antibody engineered to target the CD3... more

Close menu

Product information "Visilizumab"

Description: Visilizumab is a humanized IgG2 monoclonal antibody engineered to target the CD3 antigen on T-cells while exhibiting low Fc receptor binding activity to minimize activation-induced cytotoxicity. this unique design potentially suppresses the body's immune response through the modulation of T-cell function, and Visilizumab can be used in studies about the treatment of ulcerative colitis and Crohn's disease. Target: Others, Apoptosis. References: Qi T Yu, et al. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun,127(3):322-9.